Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Bausch & Lomb (NYSE:BLCO)

Bausch + Lomb ended BL1107 glaucoma eye drop development after a Phase 2 miss and will focus on a sustained-release GA implant.

Raccontata dabenzinga.com